<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01545180</url>
  </required_header>
  <id_info>
    <org_study_id>11415</org_study_id>
    <nct_id>NCT01545180</nct_id>
  </id_info>
  <brief_title>Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure</brief_title>
  <acronym>PH-HF</acronym>
  <official_title>Observatory: Search for Prognostic Factors of Pulmonary Hypertension Post-capillary in Heart Failure.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Cardiology Society</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CHRU Lille, Dr Nicolas LAMBLIN</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>French Cardiology Society</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will better understand the post-capillary pulmonary hypertension in heart failure,
      to determine its prognostic role and to consider specific treatment of different forms of
      pulmonary hypertension in post-capillary pulmonary heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with heart failure (HF) frequently have a post-capillary pulmonary hypertension
      (HTPcap) which has two forms: passive and reactive.

      The prognosis, prevalence and pathophysiological mechanisms of cell and tissue involved in
      the onset and reversibility of these two forms of HTPcap remain poorly understood.

      The latest recommendations of the European Society of Cardiology and the European Respiratory
      Society identify two forms of HTPcap in the IC as a function of the extent of trans-pulmonary
      gradient (GTP) measured during right heart catheterization (GTP = mPAP-Pcap): passive (GTP £
      12mmHg) and reactive (GTP&gt; 12mmHg).

      In the latter form, the increase in pulmonary pressure would be disproportionate to the
      increase in left ventricular pressures.

      This study will permit to identify hemodynamic prognostic markers of the the IC, and
      clinical, biological and hemodynamic determinants of the HTPcap in the IC.

      This will help to identify a population that could benefit from specific treatment to
      referred pulmonary artery.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prognostic</measure>
    <time_frame>2 years</time_frame>
    <description>Estimate the prognosis of different forms of HTPcap in heart failure (ejection fraction altered, stored or valvular heart disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence</measure>
    <time_frame>3 years</time_frame>
    <description>Define the prevalence of different forms of active or passive HTPcap</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phenotype</measure>
    <time_frame>3 years</time_frame>
    <description>Define the phenotypic characteristics of patients with reactive or passive HTPcap in heart failure</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">520</enrollment>
  <condition>Heart Failure</condition>
  <condition>Post-capillary Pulmonary Hypertension</condition>
  <arm_group>
    <arm_group_label>HTPcap in IC</arm_group_label>
    <description>HTPcap active and passive in a population of stable patients with heart failure (left ventricular ejection fraction impaired or preserved) and / or valvular disease who received a left right heart catheterization as part of their care.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      -  3 tubes of 6 blood for analysis of biomarkers

        -  2 tubes of 6 mL blood for DNA analysis
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Inclusion of consecutive patients recruted from cardiology departments for all
        participating centres. Participation in the study is offered to all French institutions
        (academic hospitals, general hospitals, army hospitals and private clinics) with cardiology
        units. A physician is responsible for study recruitment at each centre.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with heart failure (LVEF preserved or altered or valvular heart disease)
             defined by a history of heart failure or LVEF less than or equal to 50%.

          -  Patient with a right heart catheterization for medical reasons

          -  Medical treatment considered optimal: beta blockers, ACE inhibitors or angiotensin II
             receptor antagonists and/or aldosterone

          -  Stable Patient: No significant cardiac decompensation or change the dose of diuretics
             for 28 days.

          -  The patient has agreed and have signed consent.

        Exclusion Criteria:

          -  Patient is younger than 18 years.

          -  Patient with unstable heart failure (cardiogenic shock, acute cardiac decompensation).

          -  Coronary heart disease for which there is a maximum revascularization

          -  Organic valvular which is scheduled for surgical correction of valvular abnormality
             (plasty or replacement).

          -  Patient dialysis.

          -  PAH original pre-capillary catheterization, defined by a Pcap ≤ 15 mmHg.

          -  Patient with triple installation of PM within 90 days.

          -  Patients who underwent revascularization within 90 days.

          -  Patients who underwent mechanical ventricular assistance.

          -  Patient with severe lung infection (CPT &lt; 60% of predicted, FEV &lt; 60% predicted) or
             pulmonary embolism or respiratory failure with a paO2 in ambient air below 60mmHg or
             oxygen therapy.

          -  Patient with severe heart rhythm.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thibaud DAMY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tibaud DAMY</last_name>
    <phone>33(0)144907028</phone>
    <email>edrouet@cardio-sfc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Genevieve Mulak</last_name>
    <phone>33(0)143223333</phone>
    <email>edrouet@cardio-sfc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thibaud DAMY</last_name>
      <phone>33(0)144907028</phone>
      <email>edrouet@cardio-sfc.org</email>
    </contact>
    <contact_backup>
      <last_name>Geneviève Mulak</last_name>
      <phone>33(0)143223333</phone>
      <email>edrouet@cardio-sfc.org</email>
    </contact_backup>
    <investigator>
      <last_name>Thibaud DAMY</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology. The EuroHeart Failure survey programme-- a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003 Mar;24(5):442-63.</citation>
    <PMID>12633546</PMID>
  </reference>
  <reference>
    <citation>Lainscak M, Cleland JG, Lenzen MJ, Follath F, Komajda M, Swedberg K. International variations in the treatment and co-morbidity of left ventricular systolic dysfunction: data from the EuroHeart Failure Survey. Eur J Heart Fail. 2007 Mar;9(3):292-9. Epub 2006 Oct 4.</citation>
    <PMID>17023204</PMID>
  </reference>
  <reference>
    <citation>Metra M, Ponikowski P, Dickstein K, McMurray JJ, Gavazzi A, Bergh CH, Fraser AG, Jaarsma T, Pitsis A, Mohacsi P, Böhm M, Anker S, Dargie H, Brutsaert D, Komajda M; Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007 Jun-Jul;9(6-7):684-94. Epub 2007 May 3. Review.</citation>
    <PMID>17481947</PMID>
  </reference>
  <reference>
    <citation>Ghio S, Gavazzi A, Campana C, Inserra C, Klersy C, Sebastiani R, Arbustini E, Recusani F, Tavazzi L. Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol. 2001 Jan;37(1):183-8.</citation>
    <PMID>11153735</PMID>
  </reference>
  <reference>
    <citation>Kjaergaard J, Akkan D, Iversen KK, Kjoller E, Køber L, Torp-Pedersen C, Hassager C. Prognostic importance of pulmonary hypertension in patients with heart failure. Am J Cardiol. 2007 Apr 15;99(8):1146-50. Epub 2007 Mar 8.</citation>
    <PMID>17437745</PMID>
  </reference>
  <reference>
    <citation>Damy T, Viallet C, Lairez O, Deswarte G, Paulino A, Maison P, Vermes E, Gueret P, Adnot S, Dubois-Randé JL, Hittinger L. Comparison of four right ventricular systolic echocardiographic parameters to predict adverse outcomes in chronic heart failure. Eur J Heart Fail. 2009 Sep;11(9):818-24. doi: 10.1093/eurjhf/hfp111.</citation>
    <PMID>19696055</PMID>
  </reference>
  <reference>
    <citation>Damy T, Goode KM, Kallvikbacka-Bennett A, Lewinter C, Hobkirk J, Nikitin NP, Dubois-Randé JL, Hittinger L, Clark AL, Cleland JG. Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure. Eur Heart J. 2010 Sep;31(18):2280-90. doi: 10.1093/eurheartj/ehq245. Epub 2010 Aug 5.</citation>
    <PMID>20693169</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J. 2009 Oct;30(20):2493-537. doi: 10.1093/eurheartj/ehp297. Epub 2009 Aug 27. Erratum in: Eur Heart J. 2011 Apr;32(8):926.</citation>
    <PMID>19713419</PMID>
  </reference>
  <reference>
    <citation>Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT), Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2009 Dec;34(6):1219-63. doi: 10.1183/09031936.00139009. Epub 2009 Sep 12.</citation>
    <PMID>19749199</PMID>
  </reference>
  <reference>
    <citation>Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation. 2000 Oct 3;102(14):1718-23.</citation>
    <PMID>11015353</PMID>
  </reference>
  <reference>
    <citation>Gehlbach BK, Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004 Feb;125(2):669-82. Review.</citation>
    <PMID>14769751</PMID>
  </reference>
  <reference>
    <citation>Wharton J, Strange JW, Møller GM, Growcott EJ, Ren X, Franklyn AP, Phillips SC, Wilkins MR. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med. 2005 Jul 1;172(1):105-13. Epub 2005 Apr 7.</citation>
    <PMID>15817798</PMID>
  </reference>
  <reference>
    <citation>Nagendran J, Archer SL, Soliman D, Gurtu V, Moudgil R, Haromy A, St Aubin C, Webster L, Rebeyka IM, Ross DB, Light PE, Dyck JR, Michelakis ED. Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility. Circulation. 2007 Jul 17;116(3):238-48. Epub 2007 Jul 2.</citation>
    <PMID>17606845</PMID>
  </reference>
  <reference>
    <citation>Galiè N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G; Sildenafil Use in Pulmonary Arterial Hypertension (SUPER) Study Group. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 Nov 17;353(20):2148-57. Erratum in: N Engl J Med. 2006 Jun 1;354(22):2400-1.</citation>
    <PMID>16291984</PMID>
  </reference>
  <reference>
    <citation>Lewis GD, Shah R, Shahzad K, Camuso JM, Pappagianopoulos PP, Hung J, Tawakol A, Gerszten RE, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension. Circulation. 2007 Oct 2;116(14):1555-62. Epub 2007 Sep 4.</citation>
    <PMID>17785618</PMID>
  </reference>
  <reference>
    <citation>Lewis GD, Lachmann J, Camuso J, Lepore JJ, Shin J, Martinovic ME, Systrom DM, Bloch KD, Semigran MJ. Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation. 2007 Jan 2;115(1):59-66. Epub 2006 Dec 18.</citation>
    <PMID>17179022</PMID>
  </reference>
  <reference>
    <citation>Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Strömberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008 Oct;29(19):2388-442. doi: 10.1093/eurheartj/ehn309. Epub 2008 Sep 17. Review. Erratum in: Eur Heart J. 2010 Apr;12(4):416. Dosage error in article text. Eur Heart J. 2010 Mar;31(5):624. Dosage error in article text.</citation>
    <PMID>18799522</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 6, 2012</study_first_posted>
  <last_update_submitted>November 21, 2017</last_update_submitted>
  <last_update_submitted_qc>November 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>French Cardiology Society</investigator_affiliation>
    <investigator_full_name>Thibaud Damy</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Observatory</keyword>
  <keyword>Heart failure</keyword>
  <keyword>Post-capillary pulmonary hypertension</keyword>
  <keyword>HTPcap</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

